An extensive search of studies related to the use of FGFR2 inhibitor infigratinib for the treatment of nonresectable CCA within the PubMed, Google Scholar, Medline, and ScienceDirect databases was conducted. Here, FGFR2 is linked to cholangiocarcinoma.